Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
Rodolfo V CurielWilliam NguyenGulnara MamyrovaDerek JonesAlison EhrlichKathleen A BrindleShahriar Haji-MomenianRobert SheetsHanna KimOlcay Y JonesLisa G Ridernull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
This open-label study demonstrated abatacept may be beneficial for treatment-refractory JDM.
Keyphrases
- disease activity
- rheumatoid arthritis
- rheumatoid arthritis patients
- systemic lupus erythematosus
- ankylosing spondylitis
- open label
- interstitial lung disease
- juvenile idiopathic arthritis
- clinical trial
- squamous cell carcinoma
- randomized controlled trial
- study protocol
- phase iii
- systemic sclerosis
- combination therapy
- cell therapy
- rectal cancer